

Comment on: Matsuoka et al. (2010) Regulation of MafA Expression in Pancreatic β -Cells in *db/db* Mice With Diabetes. *Diabetes*;59:1709–1720

Nathan L. Vanderford

Matsuoka et al. (1) further define mechanisms regulating MafA levels in pancreatic islet β -cells under diabetic conditions using the *db/db* diabetic mouse model. MafA and insulin levels are shown to be reduced while c-Jun levels are increased in β -cells of *db/db* animals. Overexpression of c-Jun, but not c-Jun NH₂-terminal kinase (JNK), recapitulated this effect in MIN6 cells. c-Jun affects MafA expression at both the transcriptional and posttranslational level. This mechanism is concluded to be a probable cause of defective insulin production under diabetic conditions (1) given the role MafA plays in *insulin* expression (2,3).

Although not discussed by Matsuoka et al. (1), the JNK/c-Jun pathway has been implicated in regulating *MafA* expression (4). Inhibition of JNK, with SP600125, relieves the reduction in *MafA* and *insulin* expression that occurs under low glucose conditions in MIN6 cells (4), suggesting a similar model for reduced insulin production as described (1). The inability of JNK overexpression to reduce MafA mRNA or protein levels (1) versus the induction of *MafA* expression upon treatment with SP600125 (4) could be because of differences in substrate specificity of the isoform of JNK used (1) compared with the broad inhibition of JNK isoforms caused by SP600125. Matsuoka et al. (1) utilized a single human JNK isoform within mouse MIN6 cells; it is not clear whether this species difference affects JNK substrate specificity.

Among other significant points, Matsuoka et al. (1) further illustrate the complexity of MafA regulation in

β -cells; an array of signaling events regulate the transcriptional activity and expression (both at the gene and protein level) of MafA (1,3,4,6,7,9). Understanding the regulation of MafA is critical given its role in regulating β -cell function (2,3,5) and in generating functional β -cells from non- β -cell sources (8).

ACKNOWLEDGMENTS

No potential conflicts of interest relevant to this article were reported.

I thank Dr. B. Mark Evers for his critical reading.

REFERENCES

1. Matsuoka TA, Kaneto H, Miyatsuka T, Yamamoto T, Yamamoto K, Kato K, Shimomura I, Stein R, Matsuhisa M. Regulation of MafA expression in pancreatic β -cells in *db/db* mice with diabetes. *Diabetes* 2010;59:1709–1720
2. Andrali SS, Sampley ML, Vanderford NL, Ozcan S. Glucose regulation of insulin gene expression in pancreatic beta-cells. *Biochem J* 2008;415:1–10
3. Aramata S, Han SI, Kataoka K. Roles and regulation of transcription factor MafA in islet beta-cells. *Endocr J* 2007;54:659–666
4. Vanderford NL, Cantrell JE, Popa GJ, Ozcan S. Multiple kinases regulate MafA expression in the pancreatic beta cell line MIN6. *Arch Biochem Biophys* 2008;480:138–142
5. Zhang C, Moriguchi T, Kajihara M, Esaki R, Harada A, Shimohata H, Oishi H, Hamada M, Morito N, Hasegawa K, Kudo T, Engel JD, Yamamoto M, Takahashi S. MafA is a key regulator of glucose-stimulated insulin secretion. *Mol Cell Biol* 2005;25:4969–4976
6. Guo S, Burnette R, Zhao L, Vanderford NL, Poitout V, Hagman DK, Henderson E, Ozcan S, Wadzinski BE, Stein R. The stability and transactivation potential of the mammalian MafA transcription factor are regulated by serine 65 phosphorylation. *J Biol Chem* 2009;284:759–765
7. Kondo T, El Khattabi I, Nishimura W, Laybutt DR, Geraldine P, Shah S, King G, Bonner-Weir S, Weir G, Sharma A. p38 MAPK is a major regulator of MafA protein stability under oxidative stress. *Mol Endocrinol* 2009;23:1281–1290
8. Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. *Nature* 2008;455:627–632
9. Han SI, Aramata S, Yasuda K, Kataoka K. MafA stability in pancreatic beta cells is regulated by glucose and is dependent on its constitutive phosphorylation at multiple sites by glycogen synthase kinase 3. *Mol Cell Biol* 2007;27:6593–6605

From the Markey Cancer Center, University of Kentucky, Lexington, Kentucky.

Corresponding author: Nathan L. Vanderford, nathan.vanderford@uky.edu.

DOI: 10.2337/db10-0684

© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.